Levetiracetam
- PDF / 170,043 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 84 Downloads / 147 Views
1 S
Alcohol use disorder and behavioural disorder: case report A 64-year-old-man developed alcohol use disorder and behavioural disorder during treatment with levetiracetam for suspected secondary epileptic seizures. The man was hospitalised to the acute inpatient psychiatry unit due to behavioural disorder and alcohol abuse. He had a history of dyslipidaemia, hiatal hernia and benign prostatic hypertrophy. Ten months prior to hospitalisation, he developed herpes simplex virus encephalitis, which was treated with aciclovir. He also developed post-encephalitic residual impairment, which included mnesic failure, dysorexia, perseverative speech and fantastic confabulation. His family reported other symptoms as inadequate behaviour and irritability. No family or personal history of substance abuse was reported. His treatment medications included simvastatin, omeprazole, nimodipine and urolosin. Three months before the presentation, he started receiving levetiracetam 1000 mg/d [route not stated] for suspected secondary epileptic seizures. After the initiation of levetiracetam, he started drinking alcohol, mostly lonely at home with a daily intake of up to 600g. He also had behavioural disorder [time to reactions onsets not stated]. He had no history of alcohol abuse, mental health disorder or alcohol problem. Hence, the man’s treatment with levetiracetam was gradually changed to lacosamide. He also started receiving quetiapine for improvement of sleep patterns. Treatment with levetiracetam was successfully discontinued. After 10 days of hospitalisation, he was discharged home with lacosamide and quetiapine. Nine months after discharge from the hospital, he stayed abstinent from alcohol. As per Spanish pharmacovigilance system, causal relationship between alcohol use disorder and levetiracetam consider as possible [not all outcomes stated]. Guillama-Henriquez A, et al. Levetiracetam-Related Alcohol Abuse in a Postencephalitic Patient. Journal of Clinical Psychopharmacology 40: 632-634, No. 6, Nov-Dec 2020. 803514690 Available from: URL: http://doi.org/10.1097/JCP.0000000000001280
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
